PHAXIAM Therapeutics SA, formerly known as ERYTECH PHARMA SA, is a France-based biopharmaceutical company developing medicinal products mainly in oncology, hematology and immunology fields of business. The company relies on the use of phages, natural bacteria-killing viruses. PHAXIAM Therapeutics SA is developing a portfolio of phages targeting three of the most resistant and dangerous bacteria, which alone account for more than two-thirds of resistant nosocomial infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. It offers ESY-ASP (GRASPA), a medicinal product consisting of L-Asparaginase entrapped into human homologous red blood cells. The product is used for treatment of Acute Lymphoblastic Leukemia (ALL), a childhood cancer.

• Revenue in EUR (TTM)2.14m
• Net income in EUR-21.92m
• Incorporated2004
• Employees54.00

• Location
  Phaxiam Therapeutics SA60 avenue RockefellerLYON 69008FranceFRA
• Phone+33 478744438
• Fax+33 478755629
• Websitehttps://erytech.com/